|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Junttila MR, Puustinen P, Niemelä M, Ahola
R, Arnold H, Böttzauw T, Ala-aho R, Nielsen C, Ivaska J, Taya Y, et
al: CIP2A inhibits PP2A in human malignancies. Cell. 130:51–62.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Khanna A, Böckelman C, Hemmes A, Junttila
MR, Wiksten JP, Lundin M, Junnila S, Murphy DJ, Evan GI, Haglund C,
et al: MYC-dependent regulation and prognostic role of CIP2A in
gastric cancer. J Natl Cancer Inst. 101:793–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Teng HW, Yang SH, Lin JK, Chen WS, Lin TC,
Jiang JK, Yen CC, Li AF, Chen PC, Lan YT, et al: CIP2A is a
predictor of poor prognosis in colon cancer. J Gastrointest Surg.
16:1037–1047. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Vaarala MH, Väisänen MR and Ristimäki A:
CIP2A expression is increased in prostate cancer. J Exp Clin Cancer
Res. 29:1362010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Böckelman C, Lassus H, Hemmes A, Leminen
A, Westermarck J, Haglund C, Bützow R and Ristimäki A: Prognostic
role of CIP2A expression in serous ovarian cancer. Br J Cancer.
105:989–995. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tseng LM, Liu CY, Chang KC, Chu PY, Shiau
CW and Chen KF: CIP2A is a target of bortezomib in human triple
negative breast cancer cells. Breast Cancer Res. 14:R682012.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu Z, Ma L, Wen ZS, Hu Z, Wu FQ, Li W,
Liu J and Zhou GB: Cancerous inhibitor of PP2A is targeted by
natural compound celastrol for degradation in non-small-cell lung
cancer. Carcinogenesis. 35:905–914. 2014. View Article : Google Scholar
|
|
11
|
Côme C, Laine A, Chanrion M, Edgren H,
Mattila E, Liu X, Jonkers J, Ivaska J, Isola J, Darbon JM, et al:
CIP2A is associated with human breast cancer aggressivity. Clin
Cancer Res. 15:5092–5100. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
De P, Carlson JH, Leyland-Jones B and Dey
N: Role of 'oncogenic nexus' of CIP2A in breast oncogenesis: How
does it work? Am J Cancer Res. 5:2872–2891. 2015.
|
|
13
|
Wu Y, Gu TT and Zheng PS: CIP2A cooperates
with H-Ras to promote epithelial-mesenchymal transition in
cervical-cancer progression. Cancer Lett. 356:646–655. 2015.
View Article : Google Scholar
|
|
14
|
Cai F, Zhang L, Xiao X, Duan C, Huang Q,
Fan C, Li J, Liu X, Li S and Liu Y: Cucurbitacin B reverses
multidrug resistance by targeting CIP2A to reactivate protein
phosphatase 2A in MCF-7/adriamycin cells. Oncol Rep. 36:1180–1186.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xiao X, He Z, Cao W, Cai F, Zhang L, Huang
Q, Fan C, Duan C, Wang X, Wang J, et al: Oridonin inhibits
gefitinib-resistant lung cancer cells by suppressing
EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways. Int J Oncol.
48:2608–2618. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li GB, Fu RQ, Shen HM, Zhou J, Hu XY, Liu
YX, Li YN, Zhang HW, Liu X, Zhang YH, et al: Polyphyllin I induces
mitophagic and apoptotic cell death in human breast cancer cells by
increasing mitochondrial PINK1 levels. Oncotarget. 8:10359–10374.
2017.PubMed/NCBI
|
|
17
|
Chen JC, Hsieh MJ, Chen CJ, Lin JT, Lo YS,
Chuang YC, Chien SY and Chen MK: Polyphyllin G induce apoptosis and
autophagy in human nasopharyngeal cancer cells by modulation of AKT
and mitogen-activated protein kinase pathways in vitro and in vivo.
Oncotarget. 7:70276–70289. 2016.PubMed/NCBI
|
|
18
|
He H, Zheng L, Sun YP, Zhang GW and Yue
ZG: Steroidal saponins from Paris polyphylla suppress adhesion,
migration and invasion of human lung cancer A549 cells via
downregulating MMP-2 and MMP-9. Asian Pac J Cancer Prev.
15:10911–10916. 2014. View Article : Google Scholar
|
|
19
|
Yue G, Wei J, Qian X, Yu L, Zou Z, Guan W,
Wang H, Shen J and Liu B: Synergistic anticancer effects of
polyphyllin I and evodiamine on freshly-removed human gastric
tumors. PLoS One. 8:e651642013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Shi YM, Yang L, Geng YD, Zhang C and Kong
LY: Polyphyllin I induced-apoptosis is enhanced by inhibition of
autophagy in human hepatocellular carcinoma cells. Phytomedicine.
22:1139–1149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
22
|
Cao W, Liu Y, Zhang R, Zhang B, Wang T,
Zhu X, Mei L, Chen H, Zhang H, Ming P, et al: Homoharringtonine
induces apoptosis and inhibits STAT3 via IL-6/JAK1/STAT3 signal
pathway in Gefitinib-resistant lung cancer cells. Sci Rep.
5:84772015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bucay N, Bhagirath D, Sekhon K, Yang T,
Fukuhara S, Majid S, Shahryari V, Tabatabai Z, Greene KL, Hashimoto
Y, et al: A novel microRNA regulator of prostate cancer
epithelial-mesen-chymal transition. Cell Death Differ.
24:1263–1274. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Montanari M, Rossetti S, Cavaliere C,
D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E,
Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in
prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen CM, Lin CL, Chiou HL, Hsieh SC, Lin
CL, Cheng CW, Hung CH, Tsai JP and Hsieh YH: Loss of endothelial
cell-specific molecule 1 promotes the tumorigenicity and metastasis
of prostate cancer cells through regulation of the TIMP-1/MMP-9
expression. Oncotarget. 8:13886–13897. 2017.PubMed/NCBI
|
|
26
|
Zhang Q, Liu S, Parajuli KR, Zhang W,
Zhang K, Mo Z, Liu J, Chen Z, Yang S, Wang AR, et al:
Interleukin-17 promotes prostate cancer via MMP7-induced
epithelial-to-mesenchymal transition. Oncogene. 36:687–699. 2017.
View Article : Google Scholar :
|
|
27
|
Andreolas C, Kalogeropoulou M, Voulgari A
and Pintzas A: Fra-1 regulates vimentin during Ha-RAS-induced
epithelial mesenchymal transition in human colon carcinoma cells.
Int J Cancer. 122:1745–1756. 2008. View Article : Google Scholar
|
|
28
|
Zhao J, Ou B, Han D, Wang P, Zong Y, Zhu
C, Liu D, Zheng M, Sun J, Feng H, et al: Tumor-derived CXCL5
promotes human colorectal cancer metastasis through activation of
the ERK/Elk-1/Snail and AKT/GSK3β/β-catenin pathways. Mol Cancer.
16:702017. View Article : Google Scholar
|
|
29
|
Chang MC, Chen CA, Chen PJ, Chiang YC,
Chen YL, Mao TL, Lin HW, Lin Chiang WH and Cheng WF: Mesothelin
enhances invasion of ovarian cancer by inducing MMP-7 through
MAPK/ERK and JNK pathways. Biochem J. 442:293–302. 2012. View Article : Google Scholar
|
|
30
|
Khanna A, Rane JK, Kivinummi KK, Urbanucci
A, Helenius MA, Tolonen TT, Saramäki OR, Latonen L, Manni V,
Pimanda JE, et al: CIP2A is a candidate therapeutic target in
clinically challenging prostate cancer cell populations.
Oncotarget. 6:19661–19670. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Terracciano D, Bruzzese D, Ferro M,
Mazzarella C, Di Lorenzo G, Altieri V, Mariano A, Macchia V and Di
Carlo A: Preoperative insulin-like growth factor-binding protein-3
(IGFBP-3) blood level predicts gleason sum upgrading. Prostate.
72:100–107. 2012. View Article : Google Scholar
|
|
32
|
Terracciano D, Mazzarella C, Di Carlo A,
Mariano A, Ferro M, Di Lorenzo G, Giordano A, Altieri V, De Placido
S and Macchia V: Effects of the ErbB1/ErbB2 kinase inhibitor GW2974
on androgen-independent prostate cancer PC-3 cell line growth and
NSE, chromogranin A and osteopontin content. Oncol Rep. 24:213–217.
2010.PubMed/NCBI
|
|
33
|
Feng T, Cao W, Shen W, Zhang L, Gu X, Guo
Y, Tsai HI, Liu X, Li J, Zhang J, et al: Arctigenin inhibits STAT3
and exhibits anticancer potential in human triple-negative breast
cancer therapy. Oncotarget. 8:329–344. 2017.
|
|
34
|
Liu Y, Dong Y, Zhang B and Cheng YX: Small
compound 6-O-angeloylplenolin induces caspase-dependent apoptosis
in human multiple myeloma cells. Oncol Lett. 6:556–558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cao Z, Koochekpour S, Strup SE and
Kyprianou N: Reversion of epithelial-mesenchymal transition by a
novel agent DZ-50 via IGF binding protein-3 in prostate cancer
cells. Oncotarget. 8:78507–78519. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen HN, Yuan K, Xie N, Wang K, Huang Z,
Chen Y, Dou Q, Wu M, Nice EC, Zhou ZG, et al: PDLIM1 stabilizes the
E-cadherin/β-catenin complex to prevent epithelial-mesenchymal
transition and metastatic potential of colorectal cancer cells.
Cancer Res. 76:1122–1134. 2016. View Article : Google Scholar
|
|
37
|
Wen-Sheng W: ERK signaling pathway is
involved in p15INK4b/p16INK4a expression and HepG2 growth
inhibition triggered by TPA and Saikosaponin a. Oncogene.
22:955–963. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rincón R, Cristóbal I, Zazo S, Arpí O,
Menéndez S, Manso R, Lluch A, Eroles P, Rovira A, Albanell J, et
al: PP2A inhibition determines poor outcome and doxorubicin
resistance in early breast cancer and its activation shows
promising therapeutic effects. Oncotarget. 6:4299–4314. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tsukamoto S, Huang Y, Umeda D, Yamada S,
Yamashita S, Kumazoe M, Kim Y, Murata M, Yamada K and Tachibana H:
67-kDa laminin receptor-dependent protein phosphatase 2A (PP2A)
activation elicits melanoma-specific antitumor activity overcoming
drug resistance. J Biol Chem. 289:32671–32681. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Wang J, Okkeri J, Pavic K, Wang Z, Kauko
O, Halonen T, Sarek G, Ojala PM, Rao Z, Xu W, et al: Oncoprotein
CIP2A is stabilized via interaction with tumor suppressor PP2A/B56.
EMBO Rep. 18:437–450. 2017. View Article : Google Scholar : PubMed/NCBI
|
